Accordingly, there have been numerous studies examining signaling paradigms between estrogen and RTK signaling pathways [2-4] which have provided evidence that RTKs are able to activate estrogen receptor alpha (ERα) in breast cancers independent of its ligand estrogen. The gene discussed is ESR1; the disease is breast carcinoma.